No products in the cart.
Pre-made Ticilimumab benchmark antibody ( Whole mAb, anti-CTLA4/CTLA-4 therapeutic antibody, Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-569
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Ticilimumab biosimilar, Whole mAb, Anti-CTLA4/CTLA-4 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Tremelimumab (formerly ticilimumab, CP-675,206) is a fully human monoclonal antibody against CTLA-4. It is an immune checkpoint blocker. Previously in development by Pfizer, it is now in investigation by MedImmune, a wholly owned subsidiary of AstraZeneca. It has been undergoing human trials for the treatment of various cancers but has not attained approval for any.
| Products Name (INN Index) | Pre-Made Ticilimumab biosimilar, Whole mAb, Anti-CTLA4/CTLA-4 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody |
|---|---|
| INN Name | Ticilimumab |
| Target | CTLA4 |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | 5ggu:HL:AB/5ggv:HL |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2005 |
| Year Recommended | 2008 |
| Companies | AIO Studien gGmbH,Amgen,ARCAGY/GINECO Group,AstraZeneca,Azienda Ospedaliera Universitaria Senese,Canadian Cancer Trials Group,Charite – Universitatsmedizin Berlin,Dana-Farber Cancer Institute,Fondazi |
| Conditions Approved | NA |
| Conditions Active | Head and neck cancer,Liver cancer,Mesothelioma,Non-small cell lung cancer,Renal cell carcinoma,Small cell lung cancer,Solid tumours,Urogenital cancer,Biliary cancer,Bladder cancer,Breast cancer,Chola |
| Conditions Discontinued | Diffuse large B-cell lymphoma,Gynaecological cancer,Myelodysplastic syndromes |
| Development Tech | Abgenix XenoMouse |
| Previous Name | tremelimumab |
| Gm Offical Target Name | CTLA4 |
| Package |
Previous slide
Next slide
